Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
09 12 2020
09 12 2020
Historique:
received:
17
06
2020
accepted:
16
11
2020
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
24
6
2021
Statut:
ppublish
Résumé
Humans are repeatedly exposed to variants of influenza virus throughout their lifetime. As a result, preexisting influenza-specific memory B cells can dominate the response after infection or vaccination. Memory B cells recalled by adulthood exposure are largely reactive to conserved viral epitopes present in childhood strains, posing unclear consequences on the ability of B cells to adapt to and neutralize newly emerged strains. We sought to investigate the impact of preexisting immunity on generation of protective antibody responses to conserved viral epitopes upon influenza virus infection and vaccination in humans. We accomplished this by characterizing monoclonal antibodies (mAbs) from plasmablasts, which are predominantly derived from preexisting memory B cells. We found that, whereas some influenza infection-induced mAbs bound conserved and neutralizing epitopes on the hemagglutinin (HA) stalk domain or neuraminidase, most of the mAbs elicited by infection targeted non-neutralizing epitopes on nucleoprotein and other unknown antigens. Furthermore, most infection-induced mAbs had equal or stronger affinity to childhood strains, indicating recall of memory B cells from childhood exposures. Vaccination-induced mAbs were similarly induced from past exposures and exhibited substantial breadth of viral binding, although, in contrast to infection-induced mAbs, they targeted neutralizing HA head epitopes. Last, cocktails of infection-induced mAbs displayed reduced protective ability in mice compared to vaccination-induced mAbs. These findings reveal that both preexisting immunity and exposure type shape protective antibody responses to conserved influenza virus epitopes in humans. Natural infection largely recalls cross-reactive memory B cells against non-neutralizing epitopes, whereas vaccination harnesses preexisting immunity to target protective HA epitopes.
Identifiants
pubmed: 33298562
pii: 12/573/eabd3601
doi: 10.1126/scitranslmed.abd3601
pmc: PMC8115023
mid: NIHMS1688453
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : U19 AI057266
Pays : United States
Organisme : NIAID NIH HHS
ID : F32 AI145177
Pays : United States
Organisme : NIAID NIH HHS
ID : DP2 AI117921
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI109946
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007090
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400005C
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI097092
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI082724
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007605
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Informations de copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
Cell Host Microbe. 2019 Mar 13;25(3):367-376.e5
pubmed: 30795981
Science. 2012 Sep 14;337(6100):1343-8
pubmed: 22878502
Vaccine. 2003 May 1;21(16):1776-9
pubmed: 12686093
J Virol. 2015 Apr;89(7):3610-8
pubmed: 25589655
Nat Commun. 2018 Apr 11;9(1):1386
pubmed: 29643370
J Infect Dis. 2015 Apr 1;211(7):1051-9
pubmed: 25336731
mBio. 2015 Mar 10;6(2):e02556
pubmed: 25759506
Nature. 2003 Mar 27;422(6930):428-33
pubmed: 12660783
Sci Rep. 2018 Jul 11;8(1):10432
pubmed: 29992986
Methods Mol Biol. 2019;1904:109-145
pubmed: 30539468
Nat Commun. 2019 Apr 10;10(1):1660
pubmed: 30971703
J Virol. 2019 Apr 3;93(8):
pubmed: 30728266
Science. 2019 Oct 25;366(6464):499-504
pubmed: 31649200
J Virol Methods. 2015 Jun 1;217:55-63
pubmed: 25712563
Nature. 1982 Mar 11;296(5853):115-21
pubmed: 6174870
Nature. 2008 May 29;453(7195):667-71
pubmed: 18449194
mBio. 2017 Mar 21;8(2):
pubmed: 28325769
J Infect Dis. 2011 Dec 15;204(12):1879-85
pubmed: 21998477
Science. 2009 Apr 10;324(5924):246-51
pubmed: 19251591
Lancet Infect Dis. 2020 Jan;20(1):80-91
pubmed: 31630990
Elife. 2020 Jul 07;9:
pubmed: 32633233
J Exp Med. 2011 Jan 17;208(1):181-93
pubmed: 21220454
PLoS Pathog. 2019 Dec 19;15(12):e1008109
pubmed: 31856206
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
J Infect Dis. 2015 Oct 15;212(8):1191-9
pubmed: 25858957
Curr Opin Immunol. 2018 Aug;53:187-195
pubmed: 29890370
Clin Infect Dis. 2020 May 23;70(11):2290-2297
pubmed: 31300819
J Virol. 2013 Jun;87(12):6542-50
pubmed: 23576508
JCI Insight. 2020 Jan 16;5(1):
pubmed: 31794433
Science. 2011 Aug 12;333(6044):843-50
pubmed: 21737702
Nat Med. 2019 Jun;25(6):962-967
pubmed: 31160818
J Gen Virol. 2016 Sep;97(9):2104-2116
pubmed: 27260213
J Immunol. 2010 Aug 1;185(3):1642-9
pubmed: 20585035
J Virol. 2019 Oct 15;93(21):
pubmed: 31434733
N Engl J Med. 1972 Jun 22;286(25):1329-32
pubmed: 5027388
Science. 2014 Nov 21;346(6212):996-1000
pubmed: 25414313
Science. 2009 Oct 30;326(5953):734-6
pubmed: 19900932
mBio. 2017 Sep 19;8(5):
pubmed: 28928215
Viruses. 2016 Jun 03;8(6):
pubmed: 27271655
mBio. 2016 Jan 19;7(1):e01996-15
pubmed: 26787832
J Infect Dis. 2013 Mar 15;207(6):974-81
pubmed: 23307936
Trends Immunol. 2018 Jan;39(1):70-79
pubmed: 28867526
Nat Immunol. 2017 Apr;18(4):464-473
pubmed: 28192418
Nat Protoc. 2009;4(3):372-84
pubmed: 19247287
J Hyg (Lond). 1972 Dec;70(4):767-77
pubmed: 4509641
J Clin Invest. 2015 Mar 2;125(3):1255-68
pubmed: 25689254
Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15798-803
pubmed: 25331901
Nat Rev Drug Discov. 2015 Mar;14(3):167-82
pubmed: 25722244
Cell. 2018 Apr 5;173(2):417-429.e10
pubmed: 29625056
mBio. 2016 Apr 19;7(2):e00417-16
pubmed: 27094330
PLoS Pathog. 2016 Aug 18;12(8):e1005806
pubmed: 27537358
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20248-53
pubmed: 24277853
Sci Transl Med. 2015 Dec 2;7(316):316ra192
pubmed: 26631631
J Virol. 2013 Apr;87(8):4728-37
pubmed: 23408625
Science. 2015 Sep 18;349(6254):1301-6
pubmed: 26303961
Science. 2016 Nov 11;354(6313):722-726
pubmed: 27846599
J Infect Dis. 2018 Aug 24;218(7):1169-1174
pubmed: 29762692
J Virol. 2015 Oct 28;90(2):851-61
pubmed: 26512088
MMWR Morb Mortal Wkly Rep. 2020 Feb 21;69(7):177-182
pubmed: 32078591
J Exp Med. 1953 Dec;98(6):641-56
pubmed: 13109114
Cell Host Microbe. 2019 Mar 13;25(3):357-366.e6
pubmed: 30795982